The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices.

The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | The Swiss drugmaker has plucked an experienced scientist from Down ...

Originally developed as a more-potent follow-up to Roche's long-established CD20-directed antibody Rituxan (rituximab) for ...

If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the ...

The NDA is based on results from the Phase III evERA Breast Cancer study. Credit: NMK-Studio / Shutterstock.com. (NMK-Studio / Shutterstock.com.) Roche has obtained acceptance from the US Food and ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in its ...

If Gazyva gains approval in membranous nephropathy, it would have four approved indications under its belt as the drug’s ...

Roche has appointed leading Australian cancer researcher Prof Mark Dawson to lead its pharma Research and Early Development (pRED) division.

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a quarterly pipeline cleanout of ...

Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed ...